240 related articles for article (PubMed ID: 24889243)
1. Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.
Chotiwan N; Roehrig JT; Schlesinger JJ; Blair CD; Huang CY
Virology; 2014 May; 456-457():238-46. PubMed ID: 24889243
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.
Chan CYY; Low JZH; Gan ES; Ong EZ; Zhang SL; Tan HC; Chai X; Ghosh S; Ooi EE; Chan KR
mSphere; 2019 Sep; 4(5):. PubMed ID: 31533998
[TBL] [Abstract][Full Text] [Related]
3. Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection.
Wang M; Yang F; Huang D; Huang Y; Zhang X; Wang C; Zhang S; Zhang R
Front Cell Infect Microbiol; 2017; 7():157. PubMed ID: 28536674
[TBL] [Abstract][Full Text] [Related]
4. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
5. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.
Boonnak K; Slike BM; Donofrio GC; Marovich MA
J Immunol; 2013 Jun; 190(11):5659-65. PubMed ID: 23616574
[TBL] [Abstract][Full Text] [Related]
6. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():597. PubMed ID: 29740424
[TBL] [Abstract][Full Text] [Related]
8. Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement.
Fink AL; Williams KL; Harris E; Alvine TD; Henderson T; Schiltz J; Nilles ML; Bradley DS
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005721. PubMed ID: 28686617
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection.
Narayan R; Tripathi S
Front Cell Infect Microbiol; 2020; 10():580096. PubMed ID: 33123500
[TBL] [Abstract][Full Text] [Related]
11. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection.
Boonnak K; Slike BM; Burgess TH; Mason RM; Wu SJ; Sun P; Porter K; Rudiman IF; Yuwono D; Puthavathana P; Marovich MA
J Virol; 2008 Apr; 82(8):3939-51. PubMed ID: 18272578
[TBL] [Abstract][Full Text] [Related]
12. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection.
Wegman AD; Waldran MJ; Bahr LE; Lu JQ; Baxter KE; Thomas SJ; Waickman AT
PLoS Pathog; 2023 Aug; 19(8):e1011616. PubMed ID: 37639455
[TBL] [Abstract][Full Text] [Related]
13. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
14. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan.
Piccini LE; Carro AC; Quintana VM; Damonte EB
Virus Res; 2020 Dec; 290():198150. PubMed ID: 32866533
[TBL] [Abstract][Full Text] [Related]
15. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
[TBL] [Abstract][Full Text] [Related]
16. How antibodies alter the cell entry pathway of dengue virus particles in macrophages.
Ayala-Nunez NV; Hoornweg TE; van de Pol DP; Sjollema KA; Flipse J; van der Schaar HM; Smit JM
Sci Rep; 2016 Jul; 6():28768. PubMed ID: 27385443
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains.
Puerta-Guardo H; Mosso C; Medina F; Liprandi F; Ludert JE; del Angel RM
J Gen Virol; 2010 Feb; 91(Pt 2):394-403. PubMed ID: 19828759
[TBL] [Abstract][Full Text] [Related]
18. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.
Hughes HR; Crill WD; Chang GJ
Virol J; 2012 Jun; 9():115. PubMed ID: 22709350
[TBL] [Abstract][Full Text] [Related]
20. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro.
Nicholson CO; Costin JM; Rowe DK; Lin L; Jenwitheesuk E; Samudrala R; Isern S; Michael SF
Antiviral Res; 2011 Jan; 89(1):71-4. PubMed ID: 21093488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
